EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Integrating the Patient’s Voice into the Research Agenda for Treatment of Chemosensory Disorders

Claire Murphy iD, Pamela Dalton iD, Katie Boateng iD, Stephanie Hunter iD, Pamela Silberman iD, Jenifer Trachtman iD, Suz Schrandt iD, Bita Naimi iD, Emily Garvey iD, Paule V Joseph iD, Conner Frank iD, Abigail Albertazzi iD und 2 weitere

Chemical Senses · 2024

DOI: 10.1093/chemse/bjae020 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Chemical Senses, 2024. Verfasst von Claire Murphy und 13 weiteren Autor:innen. Beteiligte Einrichtung: Department of Psychology, San Diego State University, San Diego, CA, United States. Hauptthemen laut MEDLINE: Olfaction Disorders, COVID-19. Die Arbeit wurde bisher 3-mal zitiert (Crossref). Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: NIDCD NIH HHS, NIA NIH HHS, NIH HHS.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

World-wide some 658 million people were infected with COVID-19 and millions suffer from chemosensory impairment associated with long COVID. Current treatments for taste and smell disorders are limited. Involving patients has the potential to catalyze the dynamic exchange and development of new ideas and approaches to facilitate biomedical research and therapeutics. We assessed patients’ perceptions of the efficacy of treatments for chemosensory impairment using an online questionnaire completed by 5,815 people in the U.S. Logistic regression determined variables predictive of reported treatment efficacy for patients aged 18-24, 25-39, 40-60 and 60+ yrs. who were treated with nasal steroids, oral steroids, zinc, nasal rinse, smell training, theophylline, platelet rich plasma, and Omega 3. The most consistent predictor was age, with the majority of those 40-60 and 60+ reporting that nasal steroids, oral steroids, zinc, nasal rinse and smell training were only slightly effective or not effective at all. Many of these treatment strategies target regeneration and immune response, processes compromised by age. Only those under 40 reported more than slight efficacy of steroids or smell training. Findings emphasize the need to include patients of all ages in clinical trials. Older adults with olfactory impairment are at increased risk for Alzheimer’s disease (AD). We speculate that olfactory impairment associated with long COVID introduces the potential for a significant rise in AD. Long COVID-associated chemosensory impairment increases the urgency for translational and clinical research on novel treatment strategies. Suggestions for high priority areas for epidemiological, basic, and clinical research on chemosensory impairment follow.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Olfaction DisordersCOVID-19HumansMiddle AgedAdultMaleFemaleAdolescentYoung AdultSARS-CoV-2AgedSurveys and QuestionnairesTaste DisordersZinc

Stichwörter der Autor:innen

chemosensory disorderspatient engagementpost-acute COVIDresearch agendasmell

Substanzen

Zinc

Autor:innen und Institutionen

  • Department of Psychology, San Diego State University, San Diego, CA, United States.
  • Department of Psychiatry, University of California, San Diego, CA, United States.
  • Monell Chemical Senses Center, Philadelphia, A, United States.
  • The Smell and Taste Association of North America, Philadelphia, PA, United States.
  • Monell Chemical Senses Center, Philadelphia, PA, United States.
  • ExPPect, LLC, Arlington, VA, United States.

ORCID-Profile: Claire Murphy, Pamela Dalton, Katie Boateng, Stephanie Hunter, Pamela Silberman, Jenifer Trachtman, Suz Schrandt, Bita Naimi, Emily Garvey, Paule V Joseph, Conner Frank, Abigail Albertazzi, Gurston Nyquist, Nancy E Rawson

Förderung

  • NIDCD NIH HHS
  • NIA NIH HHS
  • NIH HHS

Zitieren

APA

Murphy, C., Dalton, P., Boateng, K., Hunter, S., Silberman, P., Trachtman, J., Schrandt, S., Naimi, B., Garvey, E., Joseph, P. V., Frank, C., Albertazzi, A., Nyquist, G., & Rawson, N. E. (2024). Integrating the Patient’s Voice into the Research Agenda for Treatment of Chemosensory Disorders. Chemical Senses. https://doi.org/10.1093/chemse/bjae020

Vancouver

Murphy C, Dalton P, Boateng K, Hunter S, Silberman P, Trachtman J, et al. Integrating the Patient’s Voice into the Research Agenda for Treatment of Chemosensory Disorders. Chemical Senses. 2024. doi:10.1093/chemse/bjae020

BibTeX
@article{Murphy2024,
  author = {Murphy, Claire and Dalton, Pamela and Boateng, Katie and Hunter, Stephanie and Silberman, Pamela and Trachtman, Jenifer and Schrandt, Suz and Naimi, Bita and Garvey, Emily and Joseph, Paule V and Frank, Conner and Albertazzi, Abigail and Nyquist, Gurston and Rawson, Nancy E},
  title = {Integrating the Patient’s Voice into the Research Agenda for Treatment of Chemosensory Disorders},
  journal = {Chemical Senses},
  year = {2024},
  doi = {10.1093/chemse/bjae020}
}
Kostenlos starten →